Table 3.
Biological DMARDs in current development, phase, status and mechanism of action
| Molecule | Molecule code | Mechanism of action | Pharmaceutical company/academy | Indications (axSpA/PsA) |
Current development phase | Current development stage | Clinical trial no |
| Izokibep | ABY 035 | IL-17A inhibitor | Inmagene Biopharmaceu-ticals/Affibody AB | axSpA PsA |
II IIb |
Terminated Recruiting |
NCT04795141 NCT05623345 |
| Netakimab* | BCD-085 | IL-17A inhibitor | Biocad | axSpA PsA |
III III |
Active, not recruiting Active, not recruiting |
NCT03447704 NCT03598751 |
| Bimekizumab | UCB-4940 | IL-17A et F inhibitor | UCB Biopharma SRL | axSpA PsA |
III III |
Completed Completed |
NCT03928743 NCT03895203 |
| Sonelokimab | IL-17A et F inhibitor | MoonLake Immunothera-peutics AG | PsA | II | Recruiting | NCT05640245 | |
| Brodalumab† | AMG-827 KHK-4827 |
IL 17 receptor inhibitor | Kyowa Kirin/ Bausch Health Americas |
axSpA PsA |
III III |
Completed Completed |
NCT02985983 NCT02024646 |
| Vunakizumab | SHR 1314 | IL-17A inhibitor | Suzhou Suncadia Biopharmaceu-ticals | axSpA PsA |
IIb II |
Recruiting Recruiting |
NCT04840485 NCT05055934 |
| Xeligekimab | GR-1501 | IL-17A inhibitor | Genrix (Shanghai) Biopharmaceu- ticals | axSpA | III | Active, not recruiting | ChiCTR2200060715 |
| JS005 | IL-17A inhibitor | Shanghai Junshi Bioscience | axSpA | II | Recruiting | NCT05212051 | |
| Gumokimab | AK111 | IL-17A inhibitor | Akeso | axSpA | II | Active, not recruiting | NCT05467995 |
| QX002N | IL-17 inhibitor | Qyuns Therapeutics | axSpA | II | Recruiting | ChiCTR2100053338 | |
| Tildrakizumab | SUNPG 1622 | IL-23 p19 inhibitor | Sun Pharmaceutical Industries | PsA | III | Recruiting | NCT04314544 |
| Neihulizumab | AbGn-168 | Immune checkpoint agonist; PSGL-1 ligand | AbGenomics B.V Taiwan Branch | PsA | II | Completed | NCT02267642 |
| Namilumab | AMG 203 | GM-CSF inhibitor | Izana Bioscience/Iqvia/Innovate UK | axSpA | II | Completed | NCT03622658 |
| Gimsilumab | KIN-1901 | GM-CSF inhibitor | Kinevant Sciences | axSpA | I | Completed | NCT04205851 |
| Interleukin 2 | Low dose recombinant human IL-2 | Iltoo Pharma | axSpA | II | Completed | NCT01988506 | |
| BCD-180 | Anti-TRBV9 monoclonal antibody | Biocad | axSpA | II | Recruiting | NCT05445076 |
*Marketed for axSpA and PsA in Russia and Belarus.
†Marketed for PsA in Japan.
axSpA, axial spondyloarthritis; DMARDs, disease-modifying antirheumatic drugs; GM-CSF, granulocyte-macrophage colony-stimulating factor; PsA, psoriatic arthritis; TRBV9, T-cell receptor beta variable 9.